HC Wainwright Has Bearish Estimate for NERV Q3 Earnings

Key Points

• HC Wainwright lowered Minerva Neurosciences’ Q3 2026 EPS estimate to a loss of $0.14 per share from a loss of $0.01, and projects a $0.50-per-share loss for full-year 2026.
• Minerva’s shares were trading down 6.5% at $4.32, well below their 12-month high of $12.46; the stock has a market capitalization of approximately $206 million.
• The company recently reported a quarterly loss of $0.14 per share, beating the consensus estimate of a $0.19 loss, while analysts maintain a consensus “Hold” rating and a $10.50 price target.

Minerva Neurosciences, Inc (NASDAQ:NERV - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2026 EPS estimates for shares of Minerva Neurosciences in a research report issued on Monday, August 10th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($0.14) per share for the quarter, down from their previous estimate of ($0.01). The consensus estimate for Minerva Neurosciences' current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Minerva Neurosciences' Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.50) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.64 EPS and FY2030 earnings at $1.67 EPS.

A number of other brokerages have also recently issued reports on NERV. Citizens Jmp began coverage on Minerva Neurosciences in a report on Wednesday, April 15th. They set a "market outperform" rating and a $14.00 target price on the stock. Wall Street Zen raised Minerva Neurosciences from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Minerva Neurosciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $10.50.

Minerva Neurosciences Trading Down 6.5%

NASDAQ NERV opened at $4.32 on Wednesday. The stock has a 50-day simple moving average of $4.50 and a 200 day simple moving average of $5.43. The company has a market capitalization of $206.28 million, a PE ratio of -0.15 and a beta of -0.10. Minerva Neurosciences has a 12 month low of $1.76 and a 12 month high of $12.46.

Minerva Neurosciences (NASDAQ:NERV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05.

Institutional Investors Weigh In On Minerva Neurosciences

Several large investors have recently modified their holdings of NERV. Seven Fleet Capital Management LP acquired a new position in shares of Minerva Neurosciences in the 1st quarter valued at approximately $6,855,000. DV Trading LLC acquired a new stake in Minerva Neurosciences during the 1st quarter worth approximately $5,358,000. Janus Henderson Group PLC raised its holdings in Minerva Neurosciences by 47,614.0% during the 1st quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company's stock worth $25,873,000 after buying an additional 4,285,259 shares during the period. Spruce Street Capital LP bought a new position in Minerva Neurosciences in the fourth quarter valued at approximately $6,655,000. Finally, Bank of America Corp DE lifted its stake in Minerva Neurosciences by 78,272.5% in the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company's stock valued at $241,000 after buying an additional 39,919 shares in the last quarter. 34.56% of the stock is currently owned by institutional investors.

Key Headlines Impacting Minerva Neurosciences

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright still projects a potential long-term earnings recovery, forecasting positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. These estimates suggest analysts see possible upside if Minerva’s pipeline and commercial plans succeed.
• Neutral Sentiment: The latest short-interest report showed no reported shares sold short and a zero-day days-to-cover ratio. However, the figures appear unreliable because both the current and prior short-interest totals were reported as zero, limiting their usefulness as a trading signal.
• Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS forecast to a loss of $0.50 from a loss of $0.20, while reducing quarterly estimates for the third and fourth quarters of 2026 to losses of $0.14 and $0.09 per share, respectively. The firm also lowered its second- and third-quarter 2027 estimates to losses of $0.11 per share.
• Negative Sentiment: The most significant revision was to fiscal 2027, with expected EPS reduced to a loss of $0.42 from previously projected earnings of $4.82. Fourth-quarter 2027 EPS was also cut to a loss of $0.11 from an earlier forecast of $1.95. The new estimates are well below the company’s current full-year consensus forecast of a $0.20 loss per share.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company's research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva's goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company's most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source